Horse Chestnut

Last Updated: September 28 2022

Horse Chestnut (Aesculus hippocastanum) is a plant extract with a group of molecules known as aescins, which are beneficial to circulatory health. Supplementation of horse chestnut appears to be beneficial for varicose veins and veinous insufficiency.

Horse Chestnut is most often used for

What else is Horse Chestnut known as?
Note that Horse Chestnut is also known as:
  • Aesculus hippocastanum
  • Conker tree
  • Rosskastanie
  • venostasin
Dosage information

Horse chestnut tends to be taken in the 400-600mg range, although it seems that the overall dose is less important than the standardization for aescin which should ultimately reach 100-150mg daily.

Supplementation tends to be divided into two daily doses divided by 12 hours (so, a morning and evening dose at 8am and 8pm as an example), which is due to the active components (aescins) requiring about 12 hours to reach baseline concentrations.

Join our supplement information course

Enter your email to get a FREE five-day course on supplements. 100% backed by science, we take an independent and unbiased approach to figure out what works (and what's a waste of time and money).

    The only 100% independent company. While everyone sells supplements, we only analyze research.

    Examine Database
    Evidence + Benefits at a glance

    Easily compare what works and what doesn't.

    Learn More

    Don't miss out on the latest research

    Enter your email and we'll keep you on top of the latest nutrition research, supplement myths, and more

      References
      2.^Dudek-Makuch M, Matławska ICoumarins in horse chestnut flowers: isolation and quantification by UPLC methodActa Pol Pharm.(2013 May-Jun)
      3.^Zlatanov MD, Antova GA, Angelova-Romova MJ, Teneva OTLipid composition of Castanea sativa Mill. and Aesculus hippocastanum fruit oilsJ Sci Food Agric.(2013 Feb)
      4.^[No authors listedAesculus hippocastanum (Horse chestnut). MonographAltern Med Rev.(2009 Sep)
      5.^Kapusta I, Janda B, Szajwaj B, Stochmal A, Piacente S, Pizza C, Franceschi F, Franz C, Oleszek WFlavonoids in horse chestnut (Aesculus hippocastanum) seeds and powdered waste water byproductsJ Agric Food Chem.(2007 Oct 17)
      6.^Hübner G, Wray V, Nahrstedt AFlavonol oligosaccharides from the seeds of Aesculus hippocastanumPlanta Med.(1999 Oct)
      7.^Dudek-Makuch M, Matławska IFlavonoids from the flowers of Aesculus hippocastanumActa Pol Pharm.(2011 May-Jun)
      11.^Lindner I, Meier C, Url A, Unger H, Grassauer A, Prieschl-Grassauer E, Doerfler PBeta-escin has potent anti-allergic efficacy and reduces allergic airway inflammationBMC Immunol.(2010 May 21)
      12.^Di Pierro F, Spinelli G, Monsù G, Alvisi G, Bacci G, Baiocchi C, Buratta M, Martinoli A, Vitali F, Agrifoglio C, Gennaioli F, Lucarelli MClinical effectiveness of a highly standardized and bioavailable mixture of flavonoids and triterpenes in the management of acute hemorroidal crisisActa Biomed.(2011 Apr)
      13.^Lang W, Mennicke WHPharmacokinetic studies on triatiated aescin in the mouse and ratArzneimittelforschung.(1972 Nov)
      14.^Wu XJ, Zhang ML, Cui XY, Gao F, He Q, Li XJ, Zhang JW, Fawcett JP, Gu JKComparative pharmacokinetics and bioavailability of escin Ia and isoescin Ia after administration of escin and of pure escin Ia and isoescin Ia in ratJ Ethnopharmacol.(2012 Jan 6)
      15.^Bässler D, Okpanyi S, Schrödter A, Loew D, Schürer M, Schulz HUBioavailability of beta-aescin from horse chestnut seed extract: comparative clinical studies of two Galenic formulationsAdv Ther.(2003 Sep-Oct)
      16.^Loew D, Schrödter A, Schwankl W, März RWMeasurement of the bioavailability of aescin-containing extractsMethods Find Exp Clin Pharmacol.(2000 Sep)
      18.^Charles SM, Zhang L, Cipolla MJ, Buchholz JN, Pearce WJRoles of cytosolic Ca2+ concentration and myofilament Ca2+ sensitization in age-dependent cerebrovascular myogenic toneAm J Physiol Heart Circ Physiol.(2010 Oct)
      20.^Fernandez SF, Huang MH, Davidson BA, Knight PR 3rd, Izzo JL JrMechanisms of angiotensin II-mediated decreases in intraneuronal Ca2+ in calcium-loaded stellate ganglion neuronsHypertension.(2005 Feb)
      23.^Arnould T, Janssens D, Michiels C, Remacle JEffect of aescine on hypoxia-induced activation of human endothelial cellsEur J Pharmacol.(1996 Nov 14)
      24.^Bougelet C, Roland IH, Ninane N, Arnould T, Remacle J, Michiels CEffect of aescine on hypoxia-induced neutrophil adherence to umbilical vein endotheliumEur J Pharmacol.(1998 Mar 12)
      26.^Moncada S, Palmer RM, Gryglewski RJMechanism of action of some inhibitors of endothelium-derived relaxing factorProc Natl Acad Sci U S A.(1986 Dec)
      27.^Pierrakos CN, Tsolakis EJ, Pozios IA, Diakos N, Charitos E, Malliaras K, Bonios MJ, Lazaris N, Papazoglou P, Venetsanakos J, Papalois A, Terrovitis JV, Nanas JNEffects of l-NAME on coronary blood flow, infarct size and the extent of the no-reflow phenomenonInt J Cardiol.(2012 Sep 27)
      29.^Alderton WK, Cooper CE, Knowles RGNitric oxide synthases: structure, function and inhibitionBiochem J.(2001 Aug 1)
      30.^Berti F, Omini C, Longiave DThe mode of action of aescin and the release of prostaglandinsProstaglandins.(1977 Aug)
      31.^Annoni F, Mauri A, Marincola F, Resele LFVenotonic activity of escin on the human saphenous veinArzneimittelforschung.(1979)
      33.^Longiave D, Omini C, Nicosia S, Berti FThe mode of action of aescin on isolated veins: relationship with PGF2 alphaPharmacol Res Commun.(1978 Feb)
      35.^Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld DThe epidemiology of chronic venous insufficiency and varicose veinsAnn Epidemiol.(2005 Mar)
      39.^Friederich HC, Vogelsberg H, Neiss AEvaluation of internally effective venous drugsZ Hautkr.(1978 Jun 1)
      41.^Pittler MH, Ernst EHorse chestnut seed extract for chronic venous insufficiencyCochrane Database Syst Rev.(2006 Jan 25)
      42.^Partsch HCompression therapy of the legs. A reviewJ Dermatol Surg Oncol.(1991 Oct)
      44.^Belcaro G, Rosaria Cesarone M, Ledda A, Cacchio M, Ruffini I, Ricci A, Ippolito E, Di Renzo A, Dugall M, Corsi M, Marino Santarelli AR, Grossi MGO-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative studyAngiology.(2008 Feb-Mar)
      46.^Hiai S, Yokoyama H, Oura HEffect of escin on adrenocorticotropin and corticosterone levels in rat plasmaChem Pharm Bull (Tokyo).(1981 Feb)
      51.^Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin MImmunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesisScience.(1995 Oct 13)
      53.^Xin W, Zhang L, Sun F, Jiang N, Fan H, Wang T, Li Z, He J, Fu FEscin exerts synergistic anti-inflammatory effects with low doses of glucocorticoids in vivo and in vitroPhytomedicine.(2011 Feb 15)
      56.^Bloemen K, Verstraelen S, Van Den Heuvel R, Witters H, Nelissen I, Schoeters GThe allergic cascade: review of the most important molecules in the asthmatic lungImmunol Lett.(2007 Oct 31)
      57.^Marshall JSMast-cell responses to pathogensNat Rev Immunol.(2004 Oct)
      59.^Shum BO, Rolph MS, Sewell WAMechanisms in allergic airway inflammation - lessons from studies in the mouseExpert Rev Mol Med.(2008 May 27)
      60.^Sipos W, Reutterer B, Frank M, Unger H, Grassauer A, Prieschl-Grassauer E, Doerfler PEscin inhibits type I allergic dermatitis in a novel porcine modelInt Arch Allergy Immunol.(2013)
      62.^Pirard J, Gillet P, Guffens JM, Defrance PDouble blind study of reparil in proctologyRev Med Liege.(1976 May 15)
      65.^Heck AM, DeWitt BA, Lukes ALPotential interactions between alternative therapies and warfarinAm J Health Syst Pharm.(2000 Jul 1)
      66.^Fujii Y, Ajima J, Oka K, Tosaka A, Takehara YBenign renal tumors detected among healthy adults by abdominal ultrasonographyEur Urol.(1995)
      67.^Eble JNAngiomyolipoma of kidneySemin Diagn Pathol.(1998 Feb)
      69.^Escribano MM, Muñoz-Bellido FJ, Velázquez E, Delgado J, Serrano P, Guardia J, Condé JContact urticaria due to aescinContact Dermatitis.(1997 Nov)
      70.^Muñoz X, Culebras M, Cruz MJ, Morell FOccupational asthma related to aescin inhalationAnn Allergy Asthma Immunol.(2006 Mar)